NASDAQ:PDEX Pro-Dex Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pro-Dex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $16.09 +0.14 (+0.88%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$15.56▼$16.2550-Day Range$13.16▼$16.5152-Week Range$12.40▼$32.00Volume6,130 shsAverage Volume9,169 shsMarket Capitalization$58.23 millionP/E Ratio18.49Dividend YieldN/APrice Target$30.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Pro-Dex Stock Forecast (MarketRank)Analyst RatingN/A0.00 Rating ScoreUpside/Downside86.5% Upside$30.00 Price TargetShort InterestHealthy0.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.24Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.60 out of 5 starsMedical Sector916th out of 1,429 stocksSurgical & Medical Instruments Industry98th out of 138 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $30.00, Pro-Dex has a forecasted upside of 86.5% from its current price of $16.09.Amount of Analyst CoveragePro-Dex has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.52% of the float of Pro-Dex has been sold short.Short Interest Ratio / Days to CoverPro-Dex has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pro-Dex has recently increased by 4.58%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPro-Dex does not currently pay a dividend.Dividend GrowthPro-Dex does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PDEX. Previous Next 2.9 News and Social Media Coverage News SentimentPro-Dex has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Pro-Dex this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pro-Dex insiders have not sold or bought any company stock.Percentage Held by Insiders41.20% of the stock of Pro-Dex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.73% of the stock of Pro-Dex is held by institutions. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Pro-Dex is 18.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 47.18.Price to Earnings Ratio vs. SectorThe P/E ratio of Pro-Dex is 18.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 42.02.Price to Book Value per Share RatioPro-Dex has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PDEX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter. Email Address About Pro-Dex (NASDAQ:PDEX)Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.Read More PDEX Stock News HeadlinesJune 22, 2022 | americanbankingnews.comStockNews.com Initiates Coverage on Pro-Dex (NASDAQ:PDEX)June 14, 2022 | finance.yahoo.comPro-Dex, Inc. (NASDAQ:PDEX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?June 14, 2022 | americanbankingnews.comPro-Dex (NASDAQ:PDEX) Coverage Initiated by Analysts at StockNews.comJune 6, 2022 | finance.yahoo.comPro-Dex, Inc. Discusses 2022 Goals and Third Quarter Results with The Stock Day PodcastMay 15, 2022 | finance.yahoo.comA number of insiders bought Pro-Dex, Inc. (NASDAQ:PDEX) stock last year, which is great news for shareholdersMay 12, 2022 | seekingalpha.comPDEX and DPSI among mid-day moversMay 5, 2022 | finance.yahoo.comPro-Dex, Inc. Announces Fiscal 2022 Third Quarter and Nine-Month ResultsApril 13, 2022 | finance.yahoo.comPro-Dex's (NASDAQ:PDEX) Returns On Capital Are Heading HigherMarch 6, 2022 | finance.yahoo.comWhat Is Pro-Dex, Inc.'s (NASDAQ:PDEX) Share Price Doing?February 24, 2022 | finance.yahoo.comPro-Dex, Inc. Discusses 2nd Quarter Sales and New Product Development with The Stock Day PodcastFebruary 4, 2022 | finance.yahoo.comPro-Dex (NASDAQ:PDEX) shareholders have earned a 36% CAGR over the last five yearsFebruary 3, 2022 | finance.yahoo.comPro-Dex, Inc. Announces Fiscal 2022 Second Quarter and Six-Month ResultsJanuary 5, 2022 | finance.yahoo.comPro-Dex, Inc.'s (NASDAQ:PDEX) Stock Is Going Strong: Is the Market Following Fundamentals?See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PDEX CUSIPN/A CIK788920 Webwww.pro-dex.com Phone(949) 769-3200Fax949-769-3281Employees117Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today7/02/2022Next Earnings (Estimated)8/25/2022Fiscal Year End6/30/2023Price Target and Rating Average Stock Price Forecast$30.00 High Stock Price Forecast$30.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+86.5%Consensus RatingN/A Rating Score (0-4)0 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)$0.87 Trailing P/E Ratio18.49 Forward P/E RatioN/A P/E GrowthN/ANet Income$4.45 million Net Margins8.50% Pretax Margin7.20% Return on Equity15.41% Return on Assets7.86% Debt Debt-to-Equity Ratio0.47 Current Ratio3.64 Quick Ratio2.10 Sales & Book Value Annual Sales$38.03 million Price / Sales1.53 Cash Flow$1.47 per share Price / Cash Flow10.91 Book Value$5.50 per share Price / Book2.93Miscellaneous Outstanding Shares3,619,000Free Float2,128,000Market Cap$58.23 million OptionableNot Optionable Beta1.11 Pro-Dex Frequently Asked Questions What is Pro-Dex's stock price forecast for 2022? 0 equities research analysts have issued 12 month price targets for Pro-Dex's shares. Their PDEX stock forecasts range from $30.00 to $30.00. On average, they anticipate Pro-Dex's stock price to reach $30.00 in the next year. This suggests a possible upside of 86.5% from the stock's current price. View analysts' price targets for Pro-Dex or view top-rated stocks among Wall Street analysts. How has Pro-Dex's stock price performed in 2022? Pro-Dex's stock was trading at $23.21 on January 1st, 2022. Since then, PDEX shares have decreased by 30.7% and is now trading at $16.09. View the best growth stocks for 2022 here. When is Pro-Dex's next earnings date? Pro-Dex is scheduled to release its next quarterly earnings announcement on Thursday, August 25th 2022. View our earnings forecast for Pro-Dex. How were Pro-Dex's earnings last quarter? Pro-Dex, Inc. (NASDAQ:PDEX) posted its earnings results on Thursday, May, 5th. The medical instruments supplier reported $0.12 earnings per share for the quarter. The medical instruments supplier earned $9.27 million during the quarter. Pro-Dex had a net margin of 8.50% and a trailing twelve-month return on equity of 15.41%. View Pro-Dex's earnings history. Who are Pro-Dex's key executives? Pro-Dex's management team includes the following people: Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 61, Pay $416.15k)Ms. Alisha K. Charlton, CFO & Corp. Sec. (Age 52, Pay $242.53k) (LinkedIn Profile)Ms. Angel Rebamontan Domingo, Director and Director of Regulatory Affairs & Quality Assurance What is Michael J. Berthelot's approval rating as Pro-Dex's CEO? 3 employees have rated Pro-Dex CEO Michael J. Berthelot on Glassdoor.com. Michael J. Berthelot has an approval rating of 85% among Pro-Dex's employees. Who are some of Pro-Dex's key competitors? Some companies that are related to Pro-Dex include Beyond Air (XAIR), SeaSpine (SPNE), Nyxoah (NYXH), InfuSystem (INFU), InfuSystem (INFU), Co-Diagnostics (CODX), OraSure Technologies (OSUR), Apyx Medical (APYX), Accuray (ARAY), Profound Medical (PROF), Quipt Home Medical (QIPT), Apollo Endosurgery (APEN), Tactile Systems Technology (TCMD), Meihua International Medical Technologies (MHUA) and DarioHealth (DRIO). View all of PDEX's competitors. What other stocks do shareholders of Pro-Dex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pro-Dex investors own include KEMET (KEM), NVIDIA (NVDA), Enterprise Products Partners (EPD), Micron Technology (MU), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA), Bank of America (BAC), Marvell Technology (MRVL) and UnitedHealth Group (UNH). What is Pro-Dex's stock symbol? Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX." How do I buy shares of Pro-Dex? Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pro-Dex's stock price today? One share of PDEX stock can currently be purchased for approximately $16.09. How much money does Pro-Dex make? Pro-Dex (NASDAQ:PDEX) has a market capitalization of $58.23 million and generates $38.03 million in revenue each year. The medical instruments supplier earns $4.45 million in net income (profit) each year or $0.87 on an earnings per share basis. How many employees does Pro-Dex have? Pro-Dex employs 117 workers across the globe. How can I contact Pro-Dex? Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The official website for Pro-Dex is www.pro-dex.com. The medical instruments supplier can be reached via phone at (949) 769-3200, via email at investor.relations@pro-dex.com, or via fax at 949-769-3281. This page (NASDAQ:PDEX) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
